Hepatitis 2017

Sessions/Tracks

Hepatitis B is a liver infection caused by the Hepatitis B virus (HBV). HBV is transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids. HBV can survive outside the body at least 7 days and still be capable of causing infection. The best way to prevent hepatitis B is by getting the hepatitis B vaccine. The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which lead to liver injury and potentially cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.

Hepatitis C is a devastating viral disease that generally progresses slowly, meaning patients often remain asymptomatic and unaware they are infected until very serious and often expensive complications emerge as a result of damage to the liver. It is estimated that about half of those infected are not aware that they carry the virus. The recent remarkable advances in treating hepatitis C built on incremental improvements achieved over the previous two decades to transform hepatitis C from a chronic, fatal disease, to an infection that with new and forthcoming treatments, can be potentially cured.

Non-viral hepatitis is an inflammation of the liver caused by toxins, drugs, or other harmful chemicals that destroy cells in the liver (Hepatocytes). Acute hepatitis damages hepatocytes, make up 70-85% of the total mass of the liver. The disease is a growing problem due to the increasing number of dietary supplements with liver side effects. If hepatitis leads to liver failure, a liver transplant is the only treatment option that can improve survival.

The best way to prevent hepatitis is by getting the hepatitis vaccines. Vaccination is safe and effective and it is recommended for all. Efforts to develop a hepatitis C vaccine started more than 20 years ago, when the hepatitis C virus was identified. The hepatitis C virus is more variable than are the viruses that cause hepatitis A and hepatitis B. Hepatitis C virus occurs in at least six genetically distinct forms with 50 subtypes. A global vaccine would have to protect against all these variants of the virus.

Hepatocellular carcinoma accounts for most liver cancers. This type of liver cancer occurs more often in men than women and is usually seen in people age 50 or older. It is commonly associated with cirrhosis and hepatitis. The incidence of hepatocellular carcinoma is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of hepatocellular carcinoma. Other risk factors can include a history of alcohol abuse.

Screening for Liver diseases has been advocated with the intention of intervening to halt its progression. Abnormal liver tests are those that measure synthesis of proteins made by the liver (albumin, clotting factors) or the liver's capacity to metabolize drugs. The impact of diagnosis of hepatitis C virus on quality of life is worse in patients aware of their viral status compared with individuals unaware of their viral status.

Liver is responsible for many critical functions within the body. It helps your body digest food, store energy, and remove poisons. If it becomes diseased or injured, the loss of those functions can cause significant damage to the body. There are over 100 different forms of liver disease that affect men, women and children. These diseases include cirrhosis, alcohol abuse, hepatitis A, B, C, D, and E, Epstein Barr virus (infectious mononucleosis), non-alcoholic fatty liver disease and iron overload (hemochromatosis). The main symptoms of liver imbalance include weakness and fatigue, weight loss, nausea, vomiting, and yellow discoloration of the skin (jaundice).

Several disorders contribute to liver disease in pregnancy such as acute fatty liver of pregnancy (AFLP) and intrahepatic cholestasis of pregnancy (IHCP), hyperemesis gravidarum and hemolysis and elevated liver enzymes and low platelets (HELLP) syndrome. Liver disease such as acute viral hepatitis can occur in pregnancy and pregnancy may occur in a patient with underlying chronic liver disease including patients with cirrhosis and portal hypertension, and patients who have undergone liver transplantation.

Liver transplantation surgery technique to replace a diseased or injured liver with a healthy liver delivered from a healthy person. The liver is involved in various metabolic functioning including metabolism of drugs and toxins, removing degradation products of normal body metabolism (for example clearance of ammonia and bilirubin from the blood), and synthesis of many important proteins and enzymes (such as factors necessary for blood to clot). Doctors or surgeons suggest liver transplant surgery to the patients who suffer from severe Drug-induced liver injury (DILI) or Chronic liver failure. This surgery carries a risk of other complications including infection, liver inflammation, blood clots, liver rejection, memory and thinking problems.

Overall, about one-third of people with HIV also have hepatitis C. Hepatitis C virus (HCV) can be transmitted in some of the same ways as HIV and hepatitis B. HIV can worsen hepatitis C. HIV not only increase the risk of liver damage, but it can also speed up the onset of liver damage following infection. People who are coinfected with HIV and HCV should work closely with health care providers in order to monitor and treat both conditions.

About Conference

Conference Series invites you to attend 5th World Congress on Hepatitis and Liver diseases (Hepatitis 2017) to be held in London, UK during August10-12, 2017. The conference highlights the theme “Early diagnosis, treatment of viral hepatitis and optimizing therapy costs”.

Hepatitis 2017 is a best platform with its well organized scientific program to the audience which includes symposiums, workshops, keynote lectures, plenary talks, panel discussions and poster sessions on latest research and technological developments in the arena as well as therapeutic aspects. The conference invites Hepatologists, Gastroenterologists, Internists, Physicians, Microbiologists, Virologists, Pathologists, Oncologists, Surgeons, Toxicologists, Researchers, Students, Business delegates and Young researchers across the globe.

Market Analysis

Hepatitis is an inflammatory condition of the liver caused by the hepatitis virus. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization. Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination. Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis B patients are vulnerable to further complications related to the liver, such as: hepatocellular carcinoma (liver cancer), liver failure, and liver cirrhosis.

Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. It has a cure rate of less than 80%, which drops below 60% in some regions of the world. The low cure rate is supplemented in most regions by a lack of an effective vaccine against hepatitis C. The global hepatitis C market is thus growing in response. Recent estimates find that about 215,000 people in the UK are chronically infected with hepatitis C.

In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.

Scope of the Conference

Hepatitis 2017 provides a great platform by gathering eminent professors, Researchers, Students and delegates to exchange new ideas. The conference will cover a wide range of topics and allow participants to discuss about the management of liver diseases. Hepatitis 2017 conference consists of keynote and plenary lectures, special sessions (Workshop and Symposium), Young Researcher Forum and Poster presentations. Best poster presenters will be judged and awarded during the conference. To encourage broad participation from all over the world Conference Series LLC is offering reduced registration fee for students.

Medical Colleges in UK

Imperial College London

University College London

King's College London

Queen Mary University of London

St. George’s, University of London

The University of Buckingham

University of Oxford

University of Cambridge

University of Southampton

Hull York Medical School

Cardiff University School of Medicine

Keele University School of Medicine

University of Glasgow

Warwick Medical School

Brighton and Sussex Medical School

Norwich Medical School

University of Aberdeen

Leicester Medical School

Swansea University Medical School

The University of Sheffield

University of St Andrews School of Medicine

University of Birmingham Medical School

Leeds School of Medicine

University of Edinburgh Medical School

Lancaster Medical School

Pharmaceutical Industries in the UK

Abbot Laboratories

Adaptimmune

Allergan

Alnylam Pharmaceuticals

AstraZeneca

Bausch & Lomb

Bayer

BioMarin Pharmaceuticals

Biota Pharmaceuticals

Bristol-Myers Squib

Cellular Therapeutics

ChemOvation

Chroma Therapeutics

Chronos Therapeutics

Chugai Pharma UK Ltd

Clovis Oncology

Convergence Pharmaceuticals

Cyclacel Pharmaceuticals

Daiichi Sankyo

Eli Lilly and Company

Enigma Diagnostics

Glaxo SmithKline

Immunocore

Innova Biosciences

IOmet Pharma

Karus Therapeutics

Martindale Pharma

MISSION Therapeutics

Morningside Pharmaceuticals Ltd

Napp Pharmaceutical

Novartis

Novo Nordisk

Novus Biologicals

Oxford BioTherapeutics

Par Pharmaceuticals

Pfizer

Pharminox

ProMetic Life Sciences

Roche

Roche

Servier

Shield Therapeutics

Shire Pharmaceuticals Limited

Silence Therapeutics

Vantia Therapeutics

Vernalis

Vernalis

Liver Associations

European Association for the Study of the Liver (EASL)

Euroliver Foundation

British Association for the Study of the Liver (BASL)

British Liver Trust - National charity for adult liver disease

American Association for the Study of Liver Diseases (AASLD)

American Hepato-Pancreato-Biliary Association (AHPBA)

American Liver Foundation (ALF)

Texas Society for Gastroenterology and Endoscopy

International Hepato Pancreato Biliary Association (IHPBA)

Canadian Association for the Study of the Liver (CASL) - Canada (CA)

Canadian Liver Foundation (CLF) - Canada (CA)

Latin American Association for the Study of the Liver (ALEH)

International Association for the Study of the Liver (IASL)

Childhood Liver Tumour Study Group (SIOPEL)

Liver Kids Australia

Children's Liver Disease Foundation (CLDF)

Hepatitis B Foundation

Hepatitis Foundation International

Asian Pacific Association for the Study of the Liver (APASL)

Hong Kong Liver Foundation - Hong Kong (HK), China

Immunization Action Coalition

International Liver Transplantation Society (ILTS)

Swiss Association for the Study of the Liver (SASL) - Switzerland (CH)

Approved treatments for Hepatitis

Epclusa

Zepatier

Daklinza

Technivie

VIEKIRA PAK

VIEKIRA XR

Harvoni

Sovaldi

Olysio

Incivek

Victrelis

Pegasys

Pegintron

Rebetol

Infergen

FDA approved drugs in 2016 forHepatology

Defitelio

Ocaliva

Companies manufacturing Liver equipment’s

Echosens

KMC Systems

Argon Medical devices Inc

Humedics

Past Conference Report

Hepatitis 2016

3rd World Congress on Hepatitis and Liver Diseases (Hepatitis-2016) organised by Conference Series was held on October 10-12, 2016 at JW Marriott Dubai, UAE. The conference highlighted the theme, “Treatment and Management strategies to eradicate Hepatitis and Liver diseases”. It is an annual meeting for the study of recent advancements and management of Hepatitis and Liver diseases.

The conference was initiated with a warm welcome note from Honorable guests and our special thanks to Dr. Arnolfo Petruzziello, National Cancer Institute, IRCCS Fondazione G. Pascale, Italy the Honorable Moderator for the conference who contributed a major part for the success of this event. The conference was marked with the presence of renowned scientists, talented young researchers, students and business delegates driving the three days event into the path of success with thought provoking keynote and plenary presentations. Active participation and generous response were received from the Organizing Committee Members. Professors, Researchers, and Students from diverse groups made this conference as one of the most successful and productive event in 2016 from Conference Series.

The highlights of the meeting were the enlightening keynote lectures from:

Andrew Vaillant, Replicor Inc, Canada on the topic, “Nucleic Acid Polymers: broad spectrum antiviral agents and their development as the backbone of new

antiviral therapies for the treatment of chronic HBV and HBV / HDV infection”.

The conference proceedings were carried out through various scientific sessions and plenary lectures:

Title: Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis by Ligita Jancoriene, Vilnius University Hospital, Lithuania.

Title: Therapeutic trial to assess the efficacy and safety of folic acid and/or vitamin B complex on hepatitis C infected patients treated with pegylated interferon and ribavirin lectured by Nermeen Nabil Ashoush, The British University in Egypt, Egypt.

Title: Circulating microRNAs as non-invasive biomarkers for the detection of different stages of liver fibrosis in Egyptian HCV patients delivered by Eman El-Ahwany, Theodor Bilharz Research Institute, Egypt.

Title: Treating patients with hepatitis C genotype 1 using Viekira Pak™ in the real world: An Australian nursing perspective given by Vince Fragomeli, Nepean Hospital, Australia.

Title: 40 years observation in Liver diseases in the Middle East presented by Makki H Fayadh, ACDS, UAE.

Conference Series has taken the privilege of felicitating Hepatitis 2016 Organizing Committee and Keynote Speakers who supported and contributed for the success of this event. Conference Series, congratulate the Best Poster awardee Andreas Christe, University Hospital of Bern, Switzerland and Makki H Fayadh, ACDS, UAE.

We are glad to inform that all accepted abstracts for the conference have been indexed in Conference Series Journal, Journal of Liver as a special issue.

We sincerely thank the Organizing Committee Members, Participants and Media Partners for their gracious presence and generous support, without which the conference would not have reached the pinnacle of success. With the unique feedback from the conference, Conference Series would like to announce the commencement of the “5th World Congress on Hepatitis and Liver Diseases” during August 10-12, 2017 in London, UK.

OMICS International takes a great pride in announcing the commencement of "World Congress on Hepatitis” during July 20-22, 2015 at Hyatt Regency Orlando International Airport, Florida, USA. The conference highlights the theme “Raising global awareness on hepatitis and fighting the stigma surrounding the disease”. It is the annual meeting for the study of Hepatitis.

With the support and contribution of the organizing committee members, we successfully hosted an event at the conference venue. Active participation and generous response were received from the Organizing Committee Members, Editorial Board Members of OMICS Group Journals, Professors, Researchers, Experts and Students from diverse groups who made this conference as one of the most successful and productive event in 2015 from OMICS International. The conference was marked with the attendance of young researchers, business delegates and students who have driven this event into the path of success.

The conference was initiated with a warm welcome note from Honorable guests and the Keynote forum lead by Dr. Mark A Feitelson, Associate Director, Temple University, USA. The proceedings went through interactive sessions and panel discussions headed by Dr. Trent W Nichols, AMRI, USA, an honorable Moderator for the conference, who contributed a major part for the success of this event.

The conference witnessed an amalgamation of peerless speakers, who enlightened the crowd with their enviable research knowledge and on various alluring topics related to the field of hepatitis, carried out through various scientific-sessions and plenary lectures:

Also, the conference proceeding was encouraged through the wonderful symposiums by Dr. Andre Jean Remy, Perpignan Hospital, France, on the title ” New tools of screening viral hepatitis in real life: The French model of care” and by Dr. Ehab Abd-El-Atty, Menoufia University, Egypt, on the title “HCC risk factors synergism in Egypt and how to prevent?”

OMICS International has taken the privilege of felicitating Hepatitis-2015 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event. OMICS International, on behalf of the conference exhibitor congratulate the Best Poster awardee for her outstanding performance in the field of Hepatocellular carcinoma and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

We are glad to inform that all accepted abstracts for the conference have been indexed in OMICS Journal of Liver and Journal ofLiver Disease and Transplantation as a special issue.

We sincerely thank the Organizing Committee Members, Editorial Board Members of OMICS Journals, Participants, Attendees, Sponsors, Exhibitors, and Media partners for their gracious presence and generous support, without which the conference would not have been possible. With the unique feedback from the conference, OMICS International would like to announce the commencement of the "2nd International Conference on Hepatology” May 9-11, 2016 in Chicago, USA and “3rd World Congress on Hepatitis and Liver Diseases" October 17-19, 2016 in Dubai, UAE.

Be a member and support us

Highlights from last year’s Convention!

Authorization Policy

By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.